Regulatory Press Releases

Net sales amounted to MSEK 174.9 (161.2), an increase of 8.5 percent (negative organic growth of 6.1 percent). The quarter was negatively impacted by the phase-out of non-strategic products in surgical instruments that began in early 2025 (MSEK 5.8) and a negative currency effect (MSEK 9.9). Adjusted for these two factors, underlying organic growth would have amounted to 3.7 percent.

The nominating committee in Stille AB (publ) (“Stille”, or “the Company”) shall consist of three members, who shall represent the three shareholders with the highest number of shares willing to participate in the nominating committee, along with the Chairman of the Board. The nominating committee shall be appointed during the fourth quarter based on the shareholding at the end of the third...

The nominating committee in Stille AB (publ) (“Stille”, or “the Company”) shall consist of three members, who shall represent the three shareholders with the highest number of shares willing to participate in the nominating committee, along with the Chairman of the Board. The nominating committee shall be appointed during the fourth quarter based on the shareholding at the end of the third...

Revenue amounted to 138.8 MSEK (127.9), an increase of 8.5 percent, of which a negative organic growth of 1.9 percent. The quarter was negatively impacted by the phase-out of non-strategic products in surgical instruments that began in early 2025 and a negative currency effect. Adjusted for these two factors, underlying organic growth would have amounted to 7.3 percent.

Stille AB (publ) announces new Executive Management team, with the appointment of Niklas Tyrén as Group CFO and Martin Richardson as Group COO.